Thank you, Chandramohan. Good morning, everyone. I'm Saurabh Paliwal from Biocon's Investor Relations team, and I would like to welcome you to this earnings call for the Q2 of fiscal 2023. I would like to indicate that all participant lines will be in the listen-only mode, and there'll be an opportunity to ask questions after the opening remarks conclude. Should you need to ask a question, please select the Raise Hand option under the Reactions tab of the Zoom application. We will call out your name and unmute your line. While asking, please begin with your name and your organization. Please note that the chat box in the Zoom application is disabled, but you can raise any technical concerns by sending us an email to investor.relations@biocon.com. Please note that this conference is being recorded. The recording will be made available on our website within a day, and the transcript of the call shall be made available subsequently. Today, to discuss the company's business performance and outlook for the quarter, we have Dr. Kiran Mazumdar-Shaw, our Executive Chairperson, Mr. Siddharth Mittal, CEO and MD of Biocon Limited, along with other senior management colleagues across our business segments, including generics, biosimilars, and research services. Before we begin, I want to remind everyone about the safe harbor related to today's earnings call. Comments made during the call may be forward-looking in nature based on management's current beliefs and expectations. It must be viewed in relation to the risks that our business faces that could cause our future results, performance or achievements to differ significantly from what is expressed or implied by such forward-looking statements. After the end of this call, if you need any further information or clarifications, please do get in touch with me. Now, I'd like to turn the call over to our chairperson for her opening remarks. Over to you, Kiran. Thank you, Saurabh. Good morning, everyone. I welcome you to Biocon's earnings call for the Q2 FY 2023. I would like to spend a minute to pay tribute to my late husband, John McCallum Marshall Shaw, former Vice Chairman of the Biocon Group. John passed away on October 24th in Bengaluru. As a key member of the board and management of Biocon since 1999, John Shaw has contributed majorly to the transformation of Biocon into a globally recognized, innovation-led biopharmaceutical company. In his 22 years with Biocon, he played a very important role in building the company, ensuring the highest levels of corporate governance, as well as contributing to the financial and strategic development of the Biocon Group. He retired from the board of directors of Biocon on July 23rd, 2021 due to health reasons. John Shaw was a man who stood tall with his values and inspired many. He was a benevolent, erudite and compassionate person who truly believed in philanthropy and believed that it would make this world a better place. He was my greatest mentor and my trusted business partner. John's vision for Biocon will continue to guide us towards our purpose of enabling equitable access to healthcare worldwide, and for Biocon to become a global leader in its chosen areas. With that, let me now turn to the earnings call. Let me start by commenting on some macroeconomic dynamics. The global economy is in its deepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022, and is likely to slide further to 2.9% in 2023, from the 6.1% that we saw in 2021. However, India is an outlier in the current geopolitical scenario. The continued war in Ukraine, which seems to be now receding, the alienation of China and other trade alignments are compelling a shift of manufacturing to countries like India. I therefore believe that India is uniquely poised for strong export-led growth in coming times. While high inflation continues to make headlines across the globe, spiraling healthcare costs do need to be addressed. Adoption of both generics and more particularly biosimilars is a necessity and not an option anymore. The Biocon Group, with its export-led business profile, is well poised to break out of the economic challenges of both recession and inflation. Research services, manufacturing, and the increasing demand for both generics and biosimilars offer attractive growth opportunities for the group. While growth is critical, sustainability is among Biocon's topmost priorities, and the company is committed to build a sustainable future. On the back of key initiatives undertaken during the past year, I'm pleased to share that in 2022, S&P Global Corporate Sustainability Assessment, released in October 2022, that Biocon has improved its ESG score to 52 from the previous year's score of 45. Let me now turn to some board updates. I would like to start by welcoming Peter Bains as an additional director on the board of Biocon Limited. With over three decades of experience in biopharmaceuticals and a successful track record of building brands, businesses, and companies, we believe that Peter's thought leadership will add tremendous value to the Biocon board. Before I turn to key financial highlights of the quarter, I would like to give you an update on the Viatris acquisition. The acquisition of Viatris' biosimilars business is expected to close shortly. Biocon Biologics will issue $1 billion of convertible securities and make an upfront payment of $2 billion to Viatris on closing the transaction. Biocon Biologics has secured $1.2 billion of debt, and the balance amount of $800 million will be funded through $650 million of equity infusion by Biocon and $150 million equity infusion by Serum. With regulatory approvals that are required to close the Viatris transaction being in place, it is, we believe, imperative to close the transaction expeditiously in order to realize and recognize the benefits of the deal. This will allow us to start transition and integration of the business at the earliest. The equity infusion of $650 million from Biocon will be funded from $230 million from its existing reserves, including the stake sale in Syngene, and the remaining $420 million dollars through mezzanine funding. We are in the process of securing investments to retire the mezzanine finance post-deal closure. Biocon stake in Biocon Biologics will be 68% post the Viatris and Serum transactions. In terms of integration and commercial success, Biocon Biologics will accrue revenue and profits emanating from the Viatris acquisition. The deal also incorporates a two-year transition services agreement, or TSA, to ensure seamless business continuity. Under the agreement, Viatris will transfer key commercial teams to Biocon Biologics. In the meanwhile, key leadership hires have been made at BBL to ensure smooth integration as well as commercial success, particularly in advanced markets, which include, of course, North America, Europe, and other advanced markets. Key leadership hires include Mr. Matthew Erick, Chief Commercial Officer, Advanced Markets. Stephen J. Fecho, Jr., Global Head of Supply Chain Management. Stephen Manzano, General Counsel, Advanced Markets. We also have onboarded key talents in our advanced market commercial teams to build market access and pricing, U.S. policy, and advocacy capabilities. We believe that this team that we have now hired puts us in a good position to address the integration and transition requirements of the deal in a very efficient manner. Let me now turn to financial highlights. At a consolidated group level, revenues for Q2 FY 2023 were up 23% on a year-on-year basis at INR 2,384 crore. Revenues from our biosimilars business and research services delivered strong year-on-year growth of 34% and 26% respectively, while our generics business grew at a healthy 18%. Core EBITDA grew 34% to INR 816 crore, representing healthy core operating margins of 35% compared to 33% in the same quarter last fiscal. Our gross R&D spend was at INR 252 crore versus INR 165 crore in the same period in the last fiscal, an increase of INR 52 crore year on year. This, of course, reflects our advancing pipeline that will drive our future growth. This spend corresponds to 16% of revenues ex Syngene. Of the 252 crores, 242 crores is expended in the P&L, while the balance amount has been capitalized. This is an INR 96 crore increase in R&D expenses over Q2 FY 2022. During the quarter, we also recorded a Forex loss of approximately INR 82 crores as compared to a gain of INR 20 crores during Q2 FY 2022. This includes INR 35 crores of foreign currency translation loss on account of the Goldman Sachs OCD investment in Biocon Biologics. With this, the reported EBITDA for the quarter was INR 535 crores versus INR 551 crores in the same period, with the EBITDA margin at 22%. Profit before tax and exceptional items stood at INR 246 crores compared to INR 276 crores during the same quarter last fiscal. The net profit for the quarter, excluding exceptional items, stood at INR 168 crores versus INR 188 crores in Q2 FY 2022. When it comes to exceptional items this quarter, I would like to basically focus on the fact that a MAT credit balance charge of INR 107 crores has been incorporated as an exceptional item. The company has decided to adopt the new tax regime of 25%, which helps Biocon to reduce its tax outflow and P&L charges on a go-forward basis. We believe this is an important step that we are taking, and this is, of course, a charge to our P&L. Professional fees, net of taxes, of INR 14 crores towards the Viatris deal also comprises part of the exceptional items. Therefore, reported net profit for the quarter is at INR 47 crores. Let me now turn to segmental performance discussions, and I will start with generics. The generics segment delivered revenues of INR 623 crore during the quarter, which is a year-on-year growth of 18%. Profit before tax for the quarter was at INR 54 crore versus INR 50 crore on a year-on-year basis, which is a growth of 9%. Sequentially as well, revenues grew by 7%. This quarter, we had two important API launches of sitagliptin and vildagliptin in the EU that were supplied from brownfield capacity expansion at our Bengaluru and Visakhapatnam plants. The generic formulations business also secured several important approvals for our vertically integrated products in the EU and rest of the world markets, providing further impetus to our geographical expansion in the quarters ahead. In terms of the pricing environment, we are seeing some moderation in raw material and logistic costs. However, the environment continues to remain challenging, especially in the US. On the CapEx front, the generics business made progress on two important projects with the completion of commissioning and qualification of our Visakhapatnam immunosuppression facility and our Bengaluru peptides facility. Process validation batches are scheduled to commence at both sites in Q3 of this fiscal. Now turning to biosimilars. Biocon Biologics recorded revenues of INR 997 crores, a year-on-year growth of 34%, fueled by the growth of insulin glargine in the US. Core EBITDA stood at INR 449 crores, which is up 48% year-on-year, and core EBITDA margin improved to 46% versus 42%, primarily on account of the rupee depreciation and accrual of PLI benefits. We continue to make good progress on our R&D pipeline, spearheaded by denosumab and ustekinumab, our biosimilar programs which are in our global phase one and phase three clinical trials. Consequently, R&D investments for the quarter increased by 142% year-on-year to INR 184 crores or 18% of BBL revenues. While this is higher than our guidance of 12%-15% of sales, we believe it will normalize once we accrue revenues from vaccines and Viatris' biosimilars businesses. This quarter's EBITDA reflects an increase of INR 108 crores in R&D investments and a non-cash foreign currency translation loss of INR 35 crores pertaining to Goldman Sachs OCD investment in BBL, which I referred to a little earlier. On a comparative basis, last year's EBITDA included a one-off gain of INR 55 crores from a mark-to-market movement on our Adagio investment. Therefore, adjusting for the foreign currency translational loss and mark-to-market gains, EBITDA is at the similar level to last fiscal. Profit before tax and exceptions stood at INR 78 crores. The Viatris-led business continues to demonstrate a strong year-on-year performance underpinned by increasing penetration of our interchangeable insulin glargine in the US. Our glargine total prescription market share is trending around 12%, while new prescriptions are at 14%. We are seeing an increased uptake of our Fulphila or pegfilgrastim in the US, and its market share has now surpassed 10%. Ogivri's market share has also started to recover following a temporary dip in Q1 and is now around 10%. In Europe, Hulio continues its strong performance in key markets such as Germany and France, where it has 18% and 9% market share respectively. We entered into a strategic out-licensing agreement with Yoshindo in Japan for commercializing two of our pipeline assets, ustekinumab and denosumab in Japan. In summary, the existing business continues to see healthy and profitable performance with an opportunity to ramp up revenues. The conclusion of the strategic deals with Viatris and Serum will transform Biocon Biologics into a leading vertically integrated global biologics enterprise, driving value for all our stakeholders. Now a short commentary on novel. Equillium, our US-based partner, announced encouraging interim data from the EQUALISE study evaluating itolizumab in patients with lupus nephritis. The study continues to enroll patients, with top-line data expected in mid 2023. An application for conducting phase 2 clinical trials with itolizumab for ulcerative colitis was approved by DCGI in October 2022. Our Boston-based associate, Bicara Therapeutics-led molecule BCA101 in combination with pembrolizumab was evaluated in frontline systemic patients with unresectable, recurrent or metastatic head and neck squamous cell carcinoma with very encouraging response rates. During this quarter, BCA101 as a monotherapy was also evaluated in patients with advanced or incurable cutaneous squamous cell carcinoma who have received previous anti-PD-1 therapy. Investor interest in Bicara has greatly increased following positive outcomes of the various clinical trials. I will now turn to research services, our Syngene International. Revenues from operations grew 26% to INR 768 crores over the corresponding quarter last year. Reported EBITDA was up 22% to INR 232 crores. Profit before tax and exceptional item was INR 130 crores, up 15% over the corresponding quarter last year. The Q2 results reflect positive performances across all divisions. Discovery services experienced sustained demand, and during the quarter, the proprietary integrated drug discovery platform, SynVent, continued to gain traction with 18 integrated programs. Development services benefited from repeat orders of existing clients, as well as an increase in the number of collaborations with emerging biopharma companies. In manufacturing services, the long-term biologics manufacturing agreement signed with Zoetis in the Q1 is expected to be transformational for the manufacturing services division in the years to come. The agreement has the potential to be worth up to $500 million over the next 10 years. I would like to conclude by saying that our performance during the H1 has demonstrated the resilience of Biocon's business model as we build the company of the future with all segments delivering strong revenue growth. We believe that the H2 of this fiscal is on a firm footing as we approach the closure of the acquisition of Viatris' biosimilars business and the vaccine alliance with Serum. Enhanced capacities and new launches will drive growth for our API and generics formulations business, while continued business momentum should help Syngene achieve its guidance for the full year. With this, I would like to open the floor to questions. Thank you. Thank you, Kiran. We'll just wait a moment for the questions to come in. As a reminder, please use the raise hand icon in the access application to ask the question. The first question is from Prakash Agarwal. Please go ahead. Yeah, hi. Good morning to all. Am I audible? Yes. Okay. Also thanks and good morning. Just wanting to understand the mezzanine funding that you spoke about. When is it expected to reverse? In the past we have talked about that we are looking for private equity investors to come in. What is the reason for the delay, if you could elaborate there? Prakash, we are in discussions with various private equity investors. As Kiran mentioned in the opening remark that we want to close the transaction very quickly so that we can realize the benefits of this acquisition and start the transition. Within the next few months, we expect retiring the short-term debt we'll be taking to fund this payout immediately and would be closing or raising the funds from private equity to square off the mezzanine finance. Okay. These are rupee debt, or? Yes, rupee debt. Around coupon of? Around 7%. 7-7.5%. Okay, understood. Secondly, if there's an update on Beva and Aspart approval timelines. I read the end of presentation that the CAPA plan's already submitted, but what is our internal thought process in terms of the approvals? Shreehas, if you can take that. Yeah. Thanks, Siddharth. You're right, Prakash, we have, post the inspection, responded to the agency with a comprehensive CAPA plan for bevacizumab, and we are awaiting the response from the agency to see that we get that approval so that we can commercialize bevacizumab in the U.S. as quickly as it's possible. You know that we already have approval from the E.U. for bevacizumab for that facility and that site. Is there any timelines that we think so that we can pin in the models? At this stage we have no indication on the timeline, but we are engaging with them to see how we can expedite. Typically, post submission of a response, it takes anywhere between 45-60 working days for them to respond, but that's usually our past experience 'cause we can't comment on behalf of the agency as to when they will come back to us. The other product from Malaysia, Aspart? For Aspart, as you know, you know, we responded to the inspection with the CAPA plan. We did receive a CRL, a Complete Response Letter, in October. The agency did point out that there is no, you know, a pending or a repeat thing from the previous CRL. There's also nothing that we see on the scientific aspect of the dossier or the science of the development of the product. They wanted to see the completion of the actions that we have committed to in the CAPA plan. They've invited us for a conversation that is currently scheduled with the agency. Post having that dialogue with the agency, we should be able to get clarity as to how we will be able to get that product to approval. Again, it's important to note that it's not a matter of if, it's a matter of when, and we should be able to provide more clarity once we have an engagement with the agency. Okay. Perfect. That helps. Lastly, on, you know, the timelines, like, so Serum deal, for just, you know, the vaccines that start effective first October. Is that understanding correct? Yes. Okay. The Mylan Viatris deal, once the payments are done, probably before December, so would the financials be added in the October to December quarter itself, or it would go to the next quarter? It would be from the date of closure. Let's assume if the closure happens by end of this month, it'll be from December 1. Okay. Thank you and all the best. Thank you, Prakash. I request all participants to limit the questions to 2 to allow other people in line to ask a question. The next question is from the line of Shyam Srinivasan from Goldman Sachs. Yeah, good morning, and thank you for taking my question. Just the first one on the operational performance at Biocon Biologics. If you could help us understand, I think you talked about Glargine market shares reaching on NRX about 14%. Are we on track for the high teens kind of market share? What are some of the dynamics that is leading us to continue the market share gains that we are seeing right now? Let me respond to that, Shyam, and maybe Matt can add further color on that. We've seen a very positive, you know, growth in the way the US market has responded to our interchangeable Glargine. While we've seen the uptick over a period of time where we started the year with a little under 3% to move into that mid-teens, closer to that mid-teens that we've talked about, it's trending in the right direction. We see Viatris gathering more customers, you know, almost on a weekly basis. We see them adding more customers to the list. We believe we're trending in the right direction towards that mid- to high-teens market share in the US that we have targeted. I'll let Matthew talk a little bit more about that. Matthew, over to you. You're probably on mute, Matthew. Sorry about that. Thank you, Shreehas. In addition to what Shreehas was saying, we continue to onboard new customers weekly in our government business, so that's trending nicely, and we continue to look to secure additional business. As we go into next quarter, we have some opportunities in which we're pursuing aggressively that could add nicely to the growth that you're seeing in the NRXs, which then will translate into the pull-through you see in TRXs. Got it. Just a second sub-question is on pricing. There's been some concerns by market participants around biosimilar pricing. You know, non-US pricing seems to be also kind of QOQ seeing deterioration. Just your comments on how pricing is trending related to your expectations. Is that the only lever for market share or you think, there are other ways to gain market share? Again, to respond to that, of course, pricing is an important element. It's something that has to be looked at. There's no going away from that discussion. Beyond that, I think most customers are looking at reliability of supply to make sure that you have a complete portfolio. They're looking at suppliers who have the ability to stay in the market with an end-to-end capability to be there in the long run. Clearly there are several levers, not just pricing. Pricing is important, but it's also important that the supplier to these customers have a track record, credibility of high quality products that they are developing and the supply ability for these demands that they're creating. I think it's a combination of this. In terms of the discounting that you talked about, it's again a factor of competition and market forces. It's been a very reasonable price decline, I would say. It's trended from that 50%-60% in most markets globally. Even in the U.S. it's been in that range. We've not seen a cliff, you know, the moment you have a biosimilar entry or even if there have been four or five players in a particular asset, we haven't seen erosion in pricing in a particular asset. I think there is pricing sanity overall, and we believe that this is likely to be a reflection of the biosimilars marketplace at least in the near term. Got it. If I may, my last question is on the generic business. This quarter has been very mixed for the players. You have seen growth maybe of a smaller base related to some of the larger incumbents. Siddharth, what are you seeing in terms of both API and formulation trends for your business for the generics? Thank you. We should continue to see some growth coming in our API business, as we have the newer capacities both from brownfield and greenfield in the coming quarters. Of course, the brownfield first, capacity expansion will give immediate boost to our growth and greenfield, capacity addition would take some time. When it comes to generic formulations, we've, as we said, we have got a few approvals in emerging markets. We also have few launches coming up in the US and the combination of these, launches plus, the growth in our base business, should generate growth in the coming quarters. Overall, the second half of this fiscal, we do expect, high single digit, growth, compared to second half of last year. Got it. Thank you and all the best. Thank you, Shyam. Next question is from Neha Manpuria from Bank of America. Yeah, thanks for taking my question. My first question is on the biosimilar business. Now we've gained market share in all of our products in the last few quarters. Glargine has particularly been good. Despite that, we've seen flat revenues, which does seem to indicate either pricing pressure not only in the U.S., but in the other markets. Just wanted to get a sense on when do you see the next step up in the revenue traction that we're seeing? That's my first question. Second, we've heard a fair bit of discussion on Humira from biosimilars for Humira from competitors. I know this is a partnered product for us, but, you know, if you could give any color on how we stand as, you know, this second set of entrants for this product? Neha, maybe I'll take the first question and I'll let Matt talk about adalimumab, subsequent to that. In terms of what we had said on the revenue numbers we had in the past said that the first two quarters of this year will be around that INR 1,000 crore mark, and then we will see it break away from that to a higher level. We'll go up in steps, and we've moved up from that INR 750 crore average to about INR 850-ish crore and then towards the INR 1,000 crore mark. We see that changing in the current quarter and moving to an upward trend. Now, specifically to the market shares and the revenue correlation that you just talked about. Two things to discuss there. One is, you're right, most of our products have recovered in market share, specifically our trastuzumab franchise in the advanced markets, which had undergone a dip in the beginning of the calendar year, has recovered very strongly and we see that trending back towards the double digits. It's certainly been a positive trend. In Glargine, too, with the NRx Matt just described, are trending towards the mid-teens. Pegfilgrastim we continue to hold that 10% market share, which is a significant threshold that we maintain. In Europe, we have continued to also grow, trastuzumab in particular, and adalimumab continues to grow there, in certain markets, Germany and France in particular. We've seen that, the euro denominated business that we've seen there has faced, pressure on the currency side with the euro depreciation to the dollar, and that has had an impact, on some of those numbers that you're seeing from a correlation perspective. We see a strong growth in the product, but unless we correct these currency impact, which we believe are transient, we will see the business continue to grow in the current quarter and going forward as well. Maybe Matthew, you can now talk about the adalimumab preparations for the U.S. Yeah. Thanks, Shreehas Tambe. Comments on our Hulio product, which is our product to Humira. Some key things we're seeing is that, you know, no product or no manufacturer has everything to the innovator. But we believe we're in a very good position as we meet with our payer customers and talk with our partner, with Viatris, that we have history. We have a lot of European history within our product in that supply, which is key to payers, and we've been able to demonstrate that with our launch of products in Europe, especially with our Hulio product, and the nice gains that we've seen in that market share. The other thing we believe as we look at launching and the timing is that we believe we're in a very good position. As you see what's going on with the payers now, there seems to be a wait and see with most of them, as they're waiting to see what's coming with all the different suppliers at the same time. We also have a uniqueness in our device itself, which we believe will be an advantage because it's very similar to the innovator. Patients will be familiar with how to use the device. We've been having nice discussions, preliminary discussions, with payers. We believe we're in a good position because most of the payers are not going to have exclusivity. They will have a N of 1 or N of 2, so that means innovator plus two biosimilars or innovator plus one biosimilars. With our history that we've demonstrated with our partner, with Viatris, and how we've already been in the market with other products the payers are familiar with, we believe it puts us in a very good position, as we get ready to launch our Hulio product. Neha, do you want to come in? Yeah. Sorry, just one follow-up, you know, on Shreehas's question. Shreehas, on the emerging market, how has that been trending quarter-over-quarter? Are we seeing growth in the ex-regulated market business, as you know, on the biosimilar side? Yes, Neha. I think the emerging markets have also been doing very well for us in all the 3 franchises that we talked about. I'll let Susheel comment specifically on it and why we believe second half will be stronger given that we're starting to see the 10 tenders which had moved to the later part of the year moving in the positive direction. Susheel, maybe you want to talk. Yes. Thank you, Shreehas. In the emerging countries, I think that we have been doing very well over not just quarter but over the years. If you see in FY 2021, we were trending at around INR 200 crores per quarter. FY 2022, about INR 250, and this year we would be trending at about, you know, INR 300 crores per quarter. Overall, the business of the emerging countries is largely tender dependent, so sometimes it gets a little lumpy in terms of the nature of the business. Overall, we are relatively confident that many of the tenders which were delayed in the quarter two will get on to quarter three, which we win. That way, the overall trend of the B2B business, as we call it in the emerging countries, is very strong for the products that we are in, especially with Insulins and with trastuzumab and now with bevacizumab. Thank you so much. Thanks, Neha. The next question is from Damayanti Kerai from HSBC. Hi. Good morning. I hope I'm audible. Yes. Okay. Thanks. My first question is simply, can you talk like how the current prescription is split between commercial and Medicare, Medicaid, patient, and how this trend has been moving in recent time? Because you have seen good pickup. That's my first question. Matthew, do you wanna take that question? Yeah. Look, I'll try. That's a very high level question, but I think it's one of channels and how you're maximizing this. There's not a traditional shift in the way people are put on the plans in the US. It's how we're taking advantage of optimizing the channels within the payers as well as the price points. So you're seeing some of these shifts, and you could see it shift back and forth. It's really taking a look at where is Medicare Part B, Part D, Medicare Advantage, where are the commercial plans and how we go to market and strategically look at that. You see some shifts, but we are taking advantage where the opportunity lends itself, and you might be seeing some of that grow in some areas versus others. Sure, Matt. In recent contracting cycle for next year, has Semglee gained a meaningful contract compared to where we were last year? I think you'll see. You definitely are seeing those market share growth in the channel. Some of the things we'll have to look at as we look at acquiring or partnering with additional customers, some of that data is not in IQVIA, but we'll see nice growth. I think more that revenue piece is one to continue to watch, because the way people report information. But I do see additional partnerships as well as additional pull-through, which you're seeing that with the NRXs in existing business coming in the future. Sure. My last question is, both your advanced markets as well as emerging markets biosimilars have picked up, so that's a good update. Can you just tell us what is the split right now in terms of biosimilar sales between advanced and emerging markets? Chini, do you wanna give a split? Roughly it's at a little around that 50% mark, just a little over 50% in advanced markets, but maybe you have a little more data on that. For the quarter, Hemanth, it's just under 60%, advanced markets. 60% under 60% for advanced market. Advanced markets, and just above 40% for emerging markets. Okay. That's helpful. Thank you. Thank you, Damayanti. The next question is from Harith Ahamed from Spark Capital. Good morning. Thanks for the opportunity. On insulin aspart, the previous CRL in 2019, the FDA had some queries on the diluent you were using, and I believe you had provided information on the same. Does the recent CRL mention anything related to the diluent, or is it just pertaining to the inspection and the GMP status? Okay. Harith, we've been able to respond to the agency on the diluent that they had asked for, and we do not see any inquiry, any further, points or comments on that. The current CRL only talks about us completing the CAPA actions to their satisfaction. There are, of course, some labeling, packaging queries which are standard whenever you have to close an application in the pre-approval process. We don't see anything beyond just the facility inspection closure in terms of the CAPA actions. How should we think of the next goal date? I missed that, in case you mentioned earlier. The agency has asked us to engage with them. They want to take us through what really is needed to close this because there is no outstanding item from the previous CRL as well, so we've closed those observations as well. I think it's important right now to see what is it that the agency is looking for before we can look at the resubmission for a new goal date at this stage. Okay. Regarding the licensing of two biosimilar assets, ustekinumab and denosumab to Yoshindo in Japan, just trying to understand how biosimilar penetration has been in that market. We've had our glargine product since 2016 under a partnership with Fujifilm. How has the experience been? How has the product ramp-up been, and what share do we have in the glargine market over there? If you could help? Yeah. Yeah, absolutely. I think a very fair question. Japan continues to be a very important market. It's still the third largest pharmaceutical market in the world and for biosimilars as well. One of the key things about Japan and its dynamics as to why to get familiar with this, we've been in Japan since 2015 when we've got that approval for insulin glargine through our partner, Fujifilm. One of the key things in Japan is that a lot of the prices there are regulated through an NHI drug price. In terms of that, the order of entry and the discounting of biosimilars become extremely critical as products are launched and institutions go through contracting for a longer period of time. There's clearly been a lot of learning for us in the Glargine commercialization process in Japan. What Japan did for us was establish our scientific credibility that we can develop products of high quality for developed markets. Back in 2015, that was a big credibility mark for Biocon overall. At this stage, I think while we've been able to understand how that market operates, and having a strong local partner like Yoshindo, who's already commercialized products like these biosimilars in the past in that competitive space, and knowing what is required to be successful in terms of the order of entry, I think we believe we have a very good opportunity here with these two assets, which between them have an opportunity of almost $700 million, split roughly equally, say, $50 million each, between ustekinumab and denosumab. Clearly, we are very excited about this, and we see that we should be able to make a success of this in Japan, Harith. Thanks, Shreehas. One on the balance sheet. There's a decline in the tangible CWIP in the consolidated balance sheet by around INR 1,300 crores. This is related to which facilities? Then the corresponding increase in the net block. Which of these facilities is contributing to this? Chini, you'll go ahead and answer. Maybe, Sid, I'll answer that. Yeah. Yeah. This pertains to capitalization of one of the drug substance facilities, that has just gone online in the quarter of July to September. Okay. Siddharth, will you be able to quantify the benefit from PLI scheme? You mentioned that in the context of improvement in margins at Biocon Biologics. Was it material? Is what I'm trying to understand. It is, as you're aware, we've been selected under the PLI scheme. The Biocon Group has been selected under the PLI scheme, which entitles us to INR 250 crore benefits over a five-six-year period. This will accrue over time. It will be now a standard in our P&L going forward. Okay. That's all from my side. Thanks. Thanks, Harith. The next question is from Masira Vansanwala from FSSA Investment Managers. Hey, thanks for taking my question. Just, you know, looking back at the history of the company, you know, the company hasn't usually taken on too much debt or done very large M&A transactions. What's different this time that gives you so much confidence to take on the debt you are taking on or the M&A? And what are you worried about, you know, as you do this? Let me start with that, you know, question by saying, I think this is a unique opportunity for the company to basically become a global leader in biosimilars. I think this is an inflection point and a huge opportunity for us in a business and, you know, a segment that is very, very differentiated. I do not think that this opportunity is something that we can ignore or even feel cautious about because we are very confident about the opportunity and the opportunity to grow. We have products in the market, we have products in the pipeline, and we have products which are to be approved very shortly. I think with all this in place, I think we have a huge opportunity to be enormously successful. I do believe that this is a debt that we have to take on to basically transform the business to the next level. We also feel very confident that this is not an unserviceable debt. It is not hugely over-leveraging the company. We are also in the process of looking at investments that can even further reduce the debts that we originally have taken on. Overall, I believe that this is a unique opportunity for the company and for very, very breakaway growth that we have never been able to see before. Thanks. Just one more question. The mezzanine financing that we're taking, is there any collateral or cash flows against which this is secured? No. It would be secured debt against the underlying assets of Biocon Limited. There will be no other collateral that'll be there. Okay. All right. Thank you. Thanks, Masira. The next question is from Sameer Baisiwala from Morgan Stanley. Yeah. Hi, thanks, and good morning, everyone. Shreehas, you must have been through with the contracting cycle for calendar 2023. If you can just share your market share outlook, especially for Glargine and the other two as well. Thanks, Sameer. For 2023, if you're referring to the U.S. insulin glargine, I think what we can indicate is that our current customers that we had contracted with we will continue to retain those. We will stay with those markets and which is why we've been confident about that growth from where we are today. You heard Matthew talk about the NRxs. We will trend towards those mid- to high-teens percent that we've guided and that seems to be moving in the right direction, Sameer. Okay, that's great. For pegfilgrastim and trastuzumab as well, if you can share your thoughts. For trastuzumab, we just talk about that franchise first. I think we did go through that dip of around 7.5%-8% early part of the year. As you see, we've clawed that back. The Viatris oncology team has really been chipping away at making sure that we, you know, gain those accounts. We've got approvals to supplement that market. We really believe there's that 10%-12% market share. We continue to build that. Going forward, I think there's a lot of focus. We are hoping bevacizumab gets approved soon. We see that happening. We're looking at pegfilgrastim being a very resilient product. We've been in that space long. We had an early mover advantage. The response overwhelmed us. Now we have significant capacity, which should allow us to play whichever segment or channel that is available to us. It's a matter of what commercial strategy our Viatris and Matt and the other teams come up with. We would have the ability to supply far greater than what it is today. Beyond the US, Sameer, what the team is really looking at at this stage is to see how we can expand our market shares in Europe as well. Over last year, if I can point out, trastuzumab Has increased its presence in Europe significantly. That's been a good positive. We see pegfilgrastim also headed in a similar direction in Europe, where the market shares will continue to grow. Overall, we see this trending in the right direction and the team is quite excited about the oncology franchise now. With Matthew and team, we feel very confident there. Okay, thanks. I just wanted to revisit a couple of key numbers for Viatris. $1 billion CCPS is being issued at what valuations? Post the transaction, the early understanding was that BBL will have $1.5 billion net debt. Is there any change to that? Hi, Sameer. The CCPS, as we mentioned, as indicated previously, is valued, is based on an equity value of $7.7 billion. The $1 billion CCPS will convert to 12.9% equity stake in BBL. There is, of course, a cap table, so it can range between 12.9%-14.9%, and it's very dependent on the IPO valuation. The debt levels $1.2 billion of debt on top of the existing $300 million of debt. On BBL's books, the debt target is $1.5 billion, which we expect to pay down, improved cash flows going forward and, of course, further equity raise from time to time. Okay, great. Chini, also, you had earlier indicated that Viatris most likely will close this year with $875 million top line and $200 million EBITDA. Any color you can share on that? Are we on track for that? Yes, Sameer. Viatris did release their Q3, that's July to September numbers. They are at $185 million for the quarter. That gives a run rate of $740 million. We see improvement in the last quarter, which it should take us closer. Keep in mind that this year, the overall, as Shreehas also mentioned, the European revenues have been impacted by the depreciation of the dollar or the euro to the dollar, sorry, and some depreciation in emerging currencies. We also have a moderate effect impacted by the delayed launch of bevacizumab as well. Okay. One final question for the mezzanine financing. Will this over the next few months be then fully replaced by private equity or how will it work? Yes. The intent is to replace it partially or fully with the private equity round. We also do have an option to raise additional funds by divesting a few more percentage stake in Syngene. We, of course, don't want to keep too much of mezzanine finance for long on the balance sheet. Okay. Quite obvious that it will be secondary sales of your stake to- That's correct. Okay. Bye. Okay. Thank you. Thank you so much. Thanks, Sameer. The next question is from Dhruv Singhal. Hi. I just wanted to ask about the potential timeline for the IPO of Biocon Biologics, and if we can expect a demerger of Syngene and Biocon Biologics eventually in the future? I think it would be a bit premature to comment on the timeline, but what we have said in the past, it will not be for the next 12 months or so. At this stage we are evaluating various options including demerger. Again, all these things would take some time before we come out with a plan for our shareholders. Dhruv, does it answer your question? Yeah. Thank you. Thank you, Dhiraj. The next question is from Tarang Agrawal from Old Bridge Capital. Hi. Good morning, everyone. Thank you for your time. Just a couple of questions from me. It's actually sort of a repeat of what's already been asked. If I look at the Biocon Biologics business for this quarter, on a quarter-on-quarter basis, you know, the revenue has been largely flattish and the core EBITDA has moved up quite nicely. Just referring to the comments, you know, explained, euro has probably depreciated about 2% on a quarter-on-quarter basis. Given the market share gains that we've made and the fact that emerging markets is roughly 40%, I'm just not able to, you know, connect the dots in terms of why the quarter-on-quarter revenues have been flat. That's number one. Number two, when I juxtapose it with how the EBITDA has actually moved up on a quarter-over-quarter basis, I'm just finding it a little difficult to understand what's been the builder here. Chini, do you want to take that then? Yeah. I'll just clarify, as Susheel indicated that the emerging markets performance is strong overall. For the quarter, it has been lower than the previous quarter. Sequentially, emerging though the underlying business is strong, the revenues booked in Q2 is lower than Q1, and that impacted the quarter or sequential growth numbers. That is one. As Susheel also indicated, that we expect a pickup of this business in the second half. Moving to the improvement in the core EBITDA, as we indicated in the opening commentary, we had the benefit of the exchange that reflects in the core EBITDA, but gets return up or down neutralized by the retranslation of our Goldman Sachs investments. While we had INR 56 crores gain on the top, we've had INR 59 crores of loss at the bottom, and that's why it's not reflected in our PBT numbers. Yes. Okay. The second is on the Viatris acquisition. So you suggested that the mezzanine financing is gonna be replacing and the financing at Biocon Biologics, would that be. I'm guessing that would be dollar-linked, right? The bank debt, Chini, is rupee-linked as well or dollar-linked? I think that's the question. In the mezzanine finance, which will come at Biocon level, will be rupee-linked. Both will be indexed to a particular benchmark in terms of how it's being priced? Well, it's all the commercial or the market rates or the lending rates, whether it's an NCD or ICD. It's all linked to the current prevailing rates. Okay. Thank you. Tarang, just to clarify, the debt and the BBL books will be a dollar-denominated debt. As you appreciate that the revenues that's coming in from the acquisition will also be dollar-denominated, and is benchmarked to the SOFR index. Tarang? Yeah, that's it from me. Thank you. Thanks, Tarang. Next question, I see Dinesh Mahajan. Hello. Good morning. Thanks for the opportunity. I would like to ask two questions. First one is pertaining to insulin glargine. What market share we have in the long-acting insulin market in India? Any number you can provide on the Basalog sales in India. Insulin glargine coming under price control in India should it impact our margins, or can it help us gain more market share in India? Maybe I'll take that. Dinesh. Yeah, go ahead. Thanks for that question. Glargine in India, Basalog is doing extremely well if you compare it versus last year. We are growing at more than 25% in a market that's sort of growing at about 3%. Most of the market changes that's happening is a switch that is happening from the leader to our brand, and that's a very good sign. In terms of market share, we used to be at 11% market share before. Now we are reaching about 13% market share, and that's a very good trend going forward for Glargine. Second question which you asked was on the pricing. Yeah. Most of the discussion that we have in the marketplace is not really about the price. It's about the services that you offer to a doctor. Because in India, as you are aware, Dinesh, this is not a tender-based market. This is largely a retail market. Doctors prescribe this product to patients. Out there in the market, it is offering your services to the doctor, being present for the patient, helping the doctor treat his patient to target. I believe we did that quite well, and that is why we are growing the market shares of Basalog. Though we are very unique in the fact that we have got some SKUs which doctors prefer, which is vials in 10 ml, 5 ml, and 3 ml, which gives significant pricing advantage to the patients as well. That's the differential we bring on the table to the patients and the doctors in the country. I would say that going forward, we would continue to grow market share, continue to be dominant with Basalog in this market. Okay. Now, you highlighted that in Indian market, the procurement is less via tendering. But if you observe procurement in CGHS, Central Government Health Scheme, or procurement by various state government health ministries, is becoming more and more tendered. Are we addressing that part of the market aggressively? If you look at it, this market is growing, you're right, but it's still about 10% or 12% of the total market, which is largely a retail market. Okay. I know there are sources like the ESIC, the army. Yeah. The defense, the railways, who procure insulins, and we have got a separate team to handle this kind of institutional business as well. Okay. Yeah. My next question is pertaining to the US market. Now, with the Viatris acquisition, we soon will be rubbing our shoulders with big corporations like Amgen, Eli Lilly and Sanofi of the world. Now, what are the three key hurdles that we face in increasing the market share of our quality products, be it oncology segment or be it Semglee or insulin aspart which we will be launching in the US market? Like, is there more resistance from medical consultants to shift to biosimilars or it is because of the high rebates which are being offered by the innovator companies to the pharmacies? How do we plan to address it? Matt, do you want to talk to that? Yeah, sure. I'll start here. Thanks for the question. Really appreciate it. As we look at the competition, we see them as any other competition. We feel with the platform and the foundation that's coming over, particularly in oncology, we have a robust platform that has these advantages in relationships already established with the physician or physician clinics, your oncology clinics, your oncology distribution. We are a known entity, and those folks that are coming from Viatris over to Biocon are maintaining those relationships. We do understand how ASP works, so we know those advantages, we know those hurdles in which we can compete very competitively against any innovator. We also are a known. We've been around for quite some time, even though it is through Viatris. The payers understand this, and also in the oncology side, the physicians are very comfortable with biosimilars. To answer your question on how we look at key winning in these markets, of course you have to have the economics. That's a starting point. You also have to have the payer contracts, meaning you have to land the formularies. What's nice that we have the foundation that we've built in the partnership together with Viatris is then we have the pull-through apparatus with the sales force. The other thing that will be successful in competing against the innovators, we have the patient services, patient education in hub services. We'll have the formulary coverage, we'll have the ability to pull through, and we have then the ability for patients to be able to afford and pay the medications. That's how we'll compete very aggressively. Coming to insulin aspart launch in India, is the launch like related to the fate of the court case or it's a separate thing and the DCGI trial thing should continue forward? Yeah, at this stage we are still awaiting regulatory approval. We do not have approval of that product, so unless the authorities approve that product, we are very eager to launch that, but we are awaiting the approval of that. Okay. Okay, that's it for me. Thank you. Thanks, Dinesh. The next question from Vipul Kumar Shah from Sundaram Investments. Vipul? Yeah. My question is to Chinappa. Biosimilar sales different 60% is regulated markets. Can you split it between U.S. and Euro region? Vipul, your audio's not too good, but I suspect that you asked for the split of the developed markets between U.S. and E.U., right? Yeah, that's correct. I don't have that exact breakup, but just our developed markets actually. I mean, one where Viatris funds it, we recognize a third of that in our profit share. They largely sell. I mean, there's the U.S., there's Europe, there is Japan, Canada, Australia, New Zealand, and also emerging markets. The sales are distributed over a much larger geography. I don't have the exact split to give you for you to- The second question relates to our Malaysia plant. Are we breaking even at EBITDA level, Malaysian facility? Can you share some financials of Malaysian facility please? Vipul, we have had profits for the last three quarters. From Q4 of last fiscal, Malaysia has been reporting profits at the PBT PAT line. Can you share the figure for the last quarter, if that is possible? INR 5 million profits for the quarter July to September. EBITDA or net? In dollars. PBT. PAT. PAT? Yes. Okay. Thank you. Thank you and all the best. Thank you, Vipul. The next question is from Tushar Manudhane from Motilal Oswal. Yeah, thanks for the opportunity. Just if you could refresh on the outlook for the Serum Alliance-led vaccine business in terms of how we look at it over the next 12 months? Sorry, sort of, I didn't follow the question. Was that, what is the question? Outlook of what? I didn't understand. I think they're asking about the Serum transaction, the visibility on that, S hreehas. Okay. Chini, do you want to give some visibility on that? Tushar, hi. As you're aware, we have a contractual arrangement with the Serum Institute of India to commercialize 100 million doses of vaccines per annum. Underlying there is a minimum commitment of revenues and profits, which is on a full year basis. As we have indicated, we could expect the revenues in the range of $300 million per annum and with EBITDA close to core EBITDA margins, which is the mid-to-high 30s%. That's the projections for the business. They will accrue on a full year basis on these lines. Can't give you a quarter by quarter commitment or guidance. Sure, that's helpful. That's it from my side. Thank you. Thanks, Tushar. We have the next question from Alankar Garude from Kotak Securities. Yeah. Hi. Good morning, everyone. My question is on the immunosuppressants facility. Can you share some details on the capacity? Which are the key products being targeted, opportunity size, focus in terms of developed versus emerging markets? Alankar, we do not give capacities of our facilities, but it's a very large facility. It's a greenfield facility in Vizag, where we'll be manufacturing products like tacrolimus, sirolimus, temsirolimus and various other products which are under development will also be manufactured there in the future. Of course, we have our existing facility in Bangalore, which has been running completely at capacity. The growth would come in from this new facility, and it will be across emerging and developed markets. Yeah. Sorry, I got muted. On that side, if I look at sirolimus, tacrolimus, the overall global market growth itself has been in that 7%-8% range. I understand we have been capacity constrained because of Bangalore. Going forward, you expect somewhat similar growth with this new capacity coming in? Or you expect to gain further market share across your existing markets in some of these products? Yeah, I think it will be both. We will gain additional market share. We have been in discussions with various customers whom we have not been able to lock in or supply in the recent years because we did not have capacities to service these customers. Plus we also expect our existing base business to grow as in more and more transplant patients are enrolled by our customers. Our base business both in formulations and API is also expected to grow. All right. Maybe one final question there. We have been present in this space for a very long time. What would be our key competitive advantages, compared to some of our global peers? I think the immunosuppression space is less competitive when you look at the global landscape. Few of our products like tacrolimus, everolimus, sirolimus, we have a large market share globally in the generic space. Of course, it's the quality, it's the science behind these drugs, which makes us differentiated compared to others. All right. Okay, that's helpful. That's it from my side. Thank you. Thank you, Alankar. The next question is from Nitin Agarwal from DAM Capital. Thanks for taking my question. I just had one question on aflibercept. A, have we decided to take on that molecule? Two, with the recent sort of patent litigation outcomes, in the PTAB, how should we look at, if we're taking the molecule on, how are we looking at the commercialization opportunity there? Nitin, we have as a part of the Viatris acquisition, we have the option to look at the acquisition of that asset, and we are proceeding with doing that. We are exercising that right to acquire Eylea. As regards to the ongoing litigation, I think it's in the public domain. Viatris is in litigation with Regeneron. Right now, it's a restricted patent litigation. The court has decided to litigate only on six patents. As you've seen, the IPRs that have recently been announced have certainly validated Viatris' view on the IP. Viatris is quite confident about its position on these patents and Viatris believes that you know it will move in the direction that it has approached it with. We're very confident there. Just a follow-up on that. You know, if I recall reading somewhere correctly, the goal date for the product was somewhere in the recent past. Is that, you know, is it correct? Where are we on the approval for the product? Any timelines for the approval? Because the filing was done some time back, I guess. As a part of the regulatory process, I think it will go through the current patent dance before it can be granted approval. Currently we are in that, or not we, but at this stage it is Viatris until the closure of the deal. It's Viatris which is in that current patent dance regulatory process. Once that is completed, only then will Viatris have that. Nitin, I think you're still mute. Thanks. This is all I had. Thank you very much. Okay. Thanks, Nitin. If you want to ask a question, we have the last few minutes, please raise your hand. Since we do not have any more questions, I'd like to take this opportunity to thank everyone for joining us in this earnings call. If you need any further clarification or have questions, please do get in touch with me. With this, I thank you very much and have a wonderful rest of the day. Bye-bye. Thank you.